The reality of complexity: concomitant genomic alterations in patients with EGFR mutations.

The advent of next-generation sequencing in the past years has allowed us to unearth a mass amount of information regarding diverse pathologies. Among these, the sequencing of cancer genomes has identified a number of oncogenic alterations which could strongly impact our understanding of tumor biology as well as our current treatment modalities.

[1]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[2]  G. Weiss,et al.  Using circulating cell-free DNA to monitor personalized cancer therapy , 2017, Critical reviews in clinical laboratory sciences.

[3]  S. Kobayashi,et al.  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.

[4]  Jian Chen,et al.  Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer , 2017, Oncotarget.

[5]  N. Normanno,et al.  Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer , 2016, Oncotarget.

[6]  Matteo Canale,et al.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.

[7]  A. Cardona,et al.  KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer: Clues For Its Potential Use in Second-Line Therapy Decision Making , 2015, American journal of clinical oncology.

[8]  R. Rosell,et al.  The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. , 2015, Lung cancer.

[9]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[10]  R. Rosell,et al.  Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[11]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[12]  M. Ladanyi,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[13]  R. Perez-Padilla,et al.  [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[14]  William Pao,et al.  Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 , 2012, Proceedings of the National Academy of Sciences.

[15]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[16]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[17]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .